Singapore Licenses New Vaccine Against Rotavirus Gastroenteritis in Children
Posted on: Tuesday, 8 November 2005, 09:01 CST
Singapore licenses new vaccine against rotavirus gastroenteritis in Children
SINGAPORE, Nov. 7 (Xinhua) -- Singapore has licensed a new vaccine which is against rotavirus gastroenteritis among children under 5 years old, Channel NewsAsia reported on Monday.
Named Rotarix, the new vaccine was developed by the world famous pharmaceutical company GlaxoSmithKline (GSK) and was tested in 11 polyclinics and three hospitals in Singapore.
The clinical trials involving some 9,000 subjects showed that the vaccine is "safe and relatively free of side effects," the report said, adding that 23 other countries has also approved the use of the vaccine.
Rotavirus gastroenteritis is a viral infection which causes severe diarrhea and kills half a million children worldwide every year.
According to the report, it is the first time that a major pharmaceutical company chooses to conduct large scale vaccine trials and have the vaccine licensed in Singapore before introducing it in the United States or Europe as usual.
Singapore has become active in participating in clinical trials as the country takes biomedical science as one of its growth engines and aims to become a regional biomedical hub.
Source: Xinhua News Agency - CEIS
Related Articles
- Federal Advisory Committee Votes to Include Newly Licensed Pentacel(R) Vaccine in Vaccines for Children Program
- ROTATEQ(R) and GARDASIL(R) Adopted By All Immunization Projects of the Centers for Disease Control and Prevention's (CDC) Vaccines for Children (VFC) Program
- Merck Updates Prescribing Information for ROTATEQ(R), the Company's Vaccine to Help Prevent Rotavirus Gastroenteritis in Infants and Children
- Singapore Urges Parents to Vaccinate Their Children againstMMR
- Nepali Gov't Provides Vaccines to Children to Reduce Child Mortality
- CDC's Advisory Committee Recommends Expanded Influenza Vaccinations for Children
- CDC Advisory Committee on Immunization Practices Votes to Recommend Inclusion of ROTATEQ(R) in the Vaccines for Children (VFC) Program
- Vaccine Against Children Diarrhea Wins FDA Approval
- Guard Young Children From Rotavirus Threat
- Effectiveness of the 2003-2004 Influenza Vaccine Among Children 6 Months to 8 Years of Age, With 1 Vs 2 Doses
 |
 |
User Comments (0)
RSS Feeds